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Aurora Kinase A Is Upregulated in Cutaneous
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Michael Hummel3, Ioannis Anagnostopoulos3, Wolfram Sterry1 and Chalid Assaf1,4
Cutaneous T-cell lymphomas (CTCLs) form a heterogeneous group of non-Hodgkin’s lymphomas characterized
by only poor prognosis in advanced stage. Despite signiﬁcant progress made in the identiﬁcation of novel genes
and pathways involved in the pathogenesis of cutaneous lymphoma, the therapeutic value of these ﬁndings has
still to be proven. Here, we demonstrate by gene expression arrays that Aurora kinase A is one of the highly
overexpressed genes of the serine/threonine kinase in CTCL. The ﬁnding was conﬁrmed by quantitative reverse
transcriptase–PCR, western blotting, and immunohistochemistry in CTCL cell lines and primary patient samples.
Moreover, treatment with a speciﬁc Aurora kinase A inhibitor blocks cell proliferation by inducing cell cycle
arrest in G2 phase, as well as apoptosis in CTCL cell lines. These data provide a promising rationale for using
Aurora kinase A inhibition as a therapeutic modality of CTCL.
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INTRODUCTION
Cutaneous T-cell lymphomas (CTCL) represent a heteroge-
neous group of extranodal T-cell lymphomas that by
deﬁnition originate through clonal expansion of neoplastic
T cells homing to the skin without further systemic involve-
ment at the time of diagnosis. Mycosis fungoides (MF) with an
incidence of 4–5/1,000,000 inhabitants per year is the most
common form of CTCL, accounting for ∼ 50% of CTCLs
(Criscione and Weinstock, 2007). Three clinical stages are
distinguished in disease progression: initial erythematous
macules (patch stage) are often followed by deeper inﬁl-
trated plaques (plaque stage), and in some cases skin tumors
may develop (tumor stage). On the other hand, Sézary
syndrome (SS), an aggressive variant of primary CTCL, is
characterized by neoplastic T cells in skin, lymph nodes, and
peripheral blood already from the beginning of the disease
(Willemze et al., 2005).
At present, there is only limited understanding on the
pathogenesis of CTCL. Cytogenetic studies and gene expres-
sion analyses of the past years could identify several genes
that may have a major role in the development and/or
progression of CTCL. The so far identiﬁed genes enclose
several known oncogenes and tumor suppressor genes that
are involved in major pathways regulating the cell cycle, cell
survival, or apoptosis—e.g., MYC, TP53, NOTCH1, E2A, and
CDKN2A (p16), and CDKN2B (p15) (Vermeer et al., 2008;
Kamstrup et al., 2010; Marks et al., 1996; Steininger et al.,
2011; Lamprecht et al., 2012; Manfé et al., 2012). These
changes were particularly identiﬁed in tumor- or plaque-stage
MF lesions, as well as in circulating tumor cells of SS patients,
owing to the high numbers of tumor cells in these situations. It
remains therefore an open question of whether these genes
are also altered in early stages and may thus contribute to
genesis or progression of CTCL.
Despite signiﬁcant progress in the identiﬁcation of genes
and pathways involved in pathogenesis of CTCL, the thera-
peutic value of these ﬁndings is still low, and there remains a
particular need for treatments of patients with advanced-
stage CTCL.
The three Aurora kinase (AURK) family members (A, B, and
C) represent serine/threonine kinases and are key regulators of
mitosis as well as diverse signal transduction pathways for
control of, e.g., centrosome function, mitotic entry, kineto-
chore function, spindle assembly, chromosome segregation,
ORIGINAL ARTICLE
1Department of Dermatology and Allergy, Skin Cancer Center Charité, Charité –
Universitätsmedizin Berlin, Berlin, Germany; 2Laboratory for Investigative
Dermatology, The Rockefeller University, New York, New York, USA; 3Institute
of Pathology, Charité – Universitätsmedizin Berlin, Berlin, Germany and
4HELIOS Klinikum Krefeld, Krefeld, Germany
Correspondence: Daniel Humme or Chalid Assaf, Department of
Dermatology, Venerology and Allergy, Skin Cancer Center Charité, Charité –
Universitätsmedizin Berlin, Charitéplatz 1, Berlin 10117, Germany.
E-mail:daniel.humme@charite.de or chalid.assaf@charite.de
5These authors contributed equally to this work.
Received 1 October 2014; revised 2 March 2015; accepted 9 March 2015;
accepted article preview online 7 April 2015; published online 7 May 2015
Abbreviations: AURK, Aurora kinase; AURKA, Aurora kinase A; cDNA,
complementary DNA; CDK, cyclin-dependent kinase; CTCL, cutaneous T-cell
lymphoma; MF, mycosis fungoides; PLK1, polo-like kinase 1; SS, Sézary
syndrome
2292 Journal of Investigative Dermatology (2015), Volume 135 © 2015 The Society for Investigative Dermatology
cytokinesis, and interaction with p53, p73, and cMYC.
Overexpression of particularly Aurora kinase A (AURKA)
has been linked to tumorigenesis and has already been
demonstrated in several hematologic malignancies as
well as in solid tumors. This resulted in the development of
several AURK inhibitors that are currently being tested in ﬁrst
clinical trials and have become a promising therapeutic
option in cancer therapy.
In an approach to further deﬁne pathways and to identify
novel potential targets for therapeutic intervention, we have
investigated gene expression proﬁles of CTCL samples of
different stages compared with normal skin by microarray and
real-time reverse transcriptase–PCR analysis. A number of
genes involved in regulation of the cell cycle and mitosis were
found to be upregulated in CTCLs. Among these, AURKA
revealed a most signiﬁcant upregulation in MF skin samples
as compared with normal skin. Overexpression of AURKA in
CTCL was also conﬁrmed by real-time reverse transcriptase–
PCR analysis of circulating tumor cells of SS patients and in
CTCL cell lines. Interestingly, inhibition of AURKA in CTCL
cell lines with MLN8237, a speciﬁc AURKA inhibitor, results
in a massive reduction of viable cells already after 24 hours.
This reduction was caused by cell cycle arrest in G2/M phase
and in addition by induction of apoptosis in tested cell lines,
indicating that AURKA inhibition could represent a promising
therapeutic strategy for CTCL patients.
RESULTS
Genes involved in cell cycle control and mitosis are signiﬁcantly
upregulated in CTCL
To identify pathways that are activated in CTCL, we per-
formed gene expression proﬁling of 13 lesional skin biopsies
of different MF patients (patch= 3, plaque= 6, tumor= 4) in
comparison with healthy control tissue from 8 patients. Using
criteria of 42.0-fold change and false discovery rate of
o0.05, we identiﬁed a series of differentially expressed
genes. Our initial analysis focused on genes encoding serine/
threonine kinases and serine/threonine/tyrosine receptor
kinases, corresponding to Gene Ontology terms GO:0004674
and GO:0004712, respectively. Within this category, we found
AURKA as one of the 10 most upregulated genes (Table 1).
Based on these ﬁndings that AURKA was one of the highest
serine/threonine/tyrosin receptor kinase expressed, and in
addition the information that a highly speciﬁc inhibitory agent
for potential treatment is already available, we focused our
further descriptive and functional analyses on AURKA.
Table 1. Top 20 upregulated serine/threonine kinases in Mycosis fungoides versus normal skin
Gene symbol
Patch/plaque (PP)
versus normal Tumor (Tu) versus normal PP versus Tu
Description
FCH FDR FCH FDR FCH FDR
PIK3CG 7.70 0.00024 13.18 0.00019 1.71 0.64 Phosphatidylinositol-4,5-bisphosphate 3-kinase,
catalytic subunit-γ
MAP4K1 4.11 0.0038 11.92 0.00018 2.90 0.20 Mitogen-activated protein kinase kinase kinase
kinase 1, HPK1
BUB1 2.36 0.22 7.69 0.018 3.26 0.39 BUB1 mitotic checkpoint serine/threonine kinase
STK17A 4.51 0.0013 7.07 0.00085 1.57 0.68 Serine/threonine kinase 17a
STK17B 4.73 0.000303 7.04 0.00025 1.49 0.67 Serine/threonine kinase 17b
AURKA 3.56 0.048 6.94 0.016 1.95 0.67 Aurora kinase A
LIMK1 2.38 0.00074 6.14 2.98E-06 2.58 0.021 LIM domain kinase 1
PRKCB 2.02 0.039 6.07 0.00018 3.01 0.058 Protein kinase C, β
PIM2 3.50 0.00030 5.94 7.26E-05 1.70 0.38 Pim-2 oncogene
PBK 1.78 0.32 5.61 0.014 3.16 0.27 PDZ-binding kinase
PLK4 1.61 0.19 3.21 0.011 1.99 0.32 Polo-like kinase 4
STK4 3.91 0.00044 4.57 0.0010 1.17 0.88 Serine/threonine kinase 4
AURKB 1.27 0.57 4.21 0.0040 3.31 0.072 Aurora kinase B
NEK6 1.64 0.092 4.15 0.00044 2.53 0.065 NIMA-related kinase 6
TGFBR1 2.01 0.042 4.11 0.0018 2.05 0.26 Transforming growth factor, β receptor 1
CHEK1 1.96 0.16 4.07 0.019 2.07 0.47 Checkpoint kinase 1
BUB1B 1.16 0.76 3.81 0.011 3.29 0.097 BUB1 mitotic checkpoint serine/threonine kinase B
BMP2K 2.11 0.0058 3.78 0.00028 1.79 0.22 BMP2 inducible kinase
MST4 1.19 0.63 3.29 0.0050 2.75 0.075 Serine/threonine protein kinase MST4
NEK2 2.24 0.23 3.36 0.14 1.5 0.84 NIMA-related kinase 2
Abbreviations: FCH, fold change; FDR, false discovery rate.
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AURKA gene ampliﬁcation is rare in CTCL
Comparative genome hybridization analyses using the bacterial
artiﬁcial chromosome arrays of four CTCL cell lines and puriﬁed
tumor cells of 20 Sézary patients revealed ampliﬁcation of the
whole chromosome 20 in the cell line SeAx as well as a410Mb
ampliﬁcation including the gene locus of AURKA, 20q13.3, in
one patient. Thus, gene duplications had been found in only 1
of 4 cell lines and in 1 of 20 investigated patient samples
(Steininger et al., 2011), thus indicating that gene duplication of
AURKA is a rare ﬁnding and largely excluding this mechanism as
common cause of AURKA overexpression in CTCL.
AURKA expression is upregulated in CTCL tumor cells as well as
in CTCL cell lines
To demonstrate that AURKA overexpression in MF skin
samples was not a result of the high number of inﬁltrating
(reactive) T cells but owing to a high expression in the tumor
cell population, AURKA expression was analyzed by immuno-
histochemistry in 19 MF and 3 SS samples from skin biopsies. As
negative control, we analyzed 10 cases of inﬂammatory
dermatoses, including 5 psoriasis and 5 eczema cases.
AURKA expression could be detected in 16/19 MF and
in 2/3 SS specimens (Figure 1a). All three stages of MF
demonstrated expression of AURKA. Moreover, immunohis-
tochemistry results revealed increasing detection rates of
AURKA in atypical cells that were judged on the basis of
morphology or pattern (epidermotropic, intraepidermal) from
patch- to tumor-stage MF. In the patch stage, up to 20% of the
inﬁltrating atypical cells stained positive for AURKA, in the
plaque stage an average of 30% (range 10–60) stained posi-
tive for AURKA, and in the tumor stage an average of 60%
(range 30–90) of AURKA-positive cells could be detected.
Small lymphocytes were noted to be at least faintly positive.
In the control skin samples with eczema and psoriasis,
inﬂammatory cells almost completely lacked AURKA positi-
vity, with overall less AURKA expression in the epidermis and
dermal tissue.
To further validate the gene expression data of MF skin
samples and to assess whether other entities of CTCL,
especially the more aggressive SS, also show upregulation
of AURKA, we analyzed its expression in 4 CTCL cell lines
(Hut-78, SeAx, MyLa, and HH), as well as in an additional set
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Figure 1. Aurora kinase A (AURKA) expression in cutaneous T-cell lymphoma (CTCL) cells. (a) Representative immunohistochemistry stainings with anti-Aurora
A antibody (AURKA) of skin samples from individuals with folliculotropic mycosis fungoides (MF) patch stage and tumor stage (scale bar=100 μm) and Sézary
syndrome (scale bar=200 μm) and as controls eczema and psoriasis (scale bar=100 μm). (b) Signiﬁcant protein expression of AURKA in four CTCL cell lines
compared with stimulated (phytohemaglutinin (PHA+) and unstimulated (PHA− ) normal CD4+ T cells is demonstrated by western blotting. Expression of
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was analyzed as loading control. Highly comparable results were obtained from two independent series of
protein extracts. (c) Reverse-transcriptase–PCR (RT-PCR) of cell lines. (c) Signiﬁcant protein expression of AURKA in four cutaneous T-cell lymphoma (CTCL) cell
lines is demonstrated by western blotting. Expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was analyzed as loading control. Highly
comparable results were obtained from two independent series of protein extracts.
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of enriched tumor cells from peripheral blood of 11 patients
with SS. As a control, sorted CD4+ memory T cells and
stimulated proliferating CD4+ cells of peripheral blood
mononuclear cells from healthy volunteers were investigated.
As demonstrated in Figure 1b and c, AURKA was expressed at
consistently high levels in CTCL lines and stimulated
proliferating CD4+ cells, with mean values largely exceeding
the levels of unstimulated memory CD4+ cells (410-fold). As
AURKA expression is linked to mitosis and therefore its
upregulation might be only owing to accelerated cell
proliferation of cell lines as compared with nonproliferating
primary T cells, we also compared the expression of primary,
circulating tumor cells in SS patients with those in healthy
controls. Of note, SS cells do not considerably proliferate in
the blood compartment (Bunn et al., 1981). As shown in
Figure 2, the tumor cells of approximately half of the patients
showed distinct upregulation of AURKA when compared with
the healthy controls. When comparing both groups, AURKA
expression was elevated by 2.4-fold in the tumor cell samples
(Po0.05). These data conﬁrmed the signiﬁcant upregulation
of AURKA in CTCL cells at the mRNA and protein levels.
The AURK inhibitor MLN8237 blocks cell proliferation by
inducing a cell cycle arrest in the G2 phase and can induce
apoptosis in CTCL cells
To determine whether AURKA may represent an appropriate
therapeutic target in CTCL, we evaluated the functional
relevance of its inhibition by using the speciﬁc AURKA inhi-
bitor MLN8237. First, we analyzed the effects of MLN8237 on
cell viability in the four CTCL cell lines Hut-78, MyLa, SeAx,
and HH. Cells were incubated with increasing concentrations
of MLN8237 for 48 hours, and the number of viable cells was
determined by WST-1 assay. All cell lines responded with a
signiﬁcant reduction of viable cell numbers when compared
with nontreated cells. Cell viability was already signiﬁcantly
reduced (Po0.05) at the lowest concentration of 0.01 μM for
3 of the 4 cell lines (SeAx, MyLa, and HH), reaching levels
between 85 and 97% (Figure 3), and reaching highly
signiﬁcant values (Po0.01) for all cell lines at 0.1 μM (range
53–66%). Viability only decreased moderately at higher
concentrations, with a maximum effect for most cell lines at
the 1.0 μM concentration (between 40 and 68%), with Hut-78
being the most sensitive cell line. These effects were
comparable to that found in phytohemaglutinin-stimulated
proliferating CD4+ T cells (Figure 3a and b). No effect on cell
viability was seen in unstimulated primary T cells (not shown).
To elucidate the mechanisms leading to decreased numbers
of viable cells after AURKA inhibition, we analyzed the DNA
content of cells at 24 hours after incubation with MLN8237 by
staining ethanol-ﬁxed cells with propidium iodide (Figure 4a
and b). All cell lines revealed a decrease of cells in G0/G1 cell
cycle phase, whereas the relative number of cells in G2/M
phase were strongly increased, indicating a block in this cell
cycle phase. The maximum effect was again reached at
concentrations between 0.1 and 1 μM, with Hut-78 being the
most sensitive cell line. In addition to an arrest in the cell
cycle, Hut78 cells also showed a signiﬁcant increase in the
number of apoptotic cells characterized by DNA contents less
than those in cells in G0/G1 (sub-G1), as well as an
appearance of hyperdiploid cells (Figure 4b).
Induction of apoptosis in Hut-78 was strongly supported by
western blotting for activated caspase-3 cleavage products
(17 and 19 kDa). In contrast, caspase-3 activation was not
signiﬁcantly enhanced in MyLa, clearly in parallel with the
diminished induction of apoptosis in these cells (Figure 4c).
The potential factors leading to apoptosis through AURKA
inhibition are summarized in Figure 5.
DISCUSSION
Cutaneous lymphomas form a diverse group of non-Hodg-
kin’s lymphomas carrying a poor prognosis in its advanced
stage, and therefore they are in need of more effective
therapies. Here we demonstrate, to our knowledge for the ﬁrst
time, that AURKA is strongly expressed in CTCL cell lines and
primary tumor cells. AURKA is among the top upregulated
genes coding for proteins with serine/threonine/tyrosine
kinase activity, as identiﬁed by gene expression proﬁling of
lesional skin. These ﬁndings were conﬁrmed by quantitative
real-time reverse transcriptase–PCR and western blotting
in all investigated CTCL cell lines and tumor cells of SS
patients showing high levels of AURKA expression, with mean
values signiﬁcantly exceeding the levels of normal CD4+
memory cells.
AURKs are essential for cell proliferation, regulating cell
cycle transition from G2, formation of the mitotic spindle,
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Figure 2. Aurora kinase A (AURKA) expression in Sézary syndrome (SS)
patients and healthy controls. The mRNA expression of AURKA was
quantiﬁed by quantitative reverse-transcriptase–PCR (RT-PCR) in CD4+ cells
of SS patients with high numbers of circulating tumor cells and CD4+ memory
T cells of healthy volunteers. (a) AURKA expression values of individual
samples relative to TATA box–binding protein (TBP). Error bars indicate s.e.m.
normalized expression values of triplicates. (b) Whisker-box plot of the
expression ratio between SS samples and healthy controls. The dotted line
represents the median value, the box area encompasses 50% of all
observations, and the whiskers represent the outer 50% of observations.
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centrosome maturation, and separation (Andrews et al., 2003;
Hirota et al., 2003; Vader et al., 2008). There are three human
homologs of AURKs, A, B, and C, that share a high degree of
sequence homology. AURKA is in principle expressed in most
normal cells; however, in line with our ﬁndings, over-
expression of AURKs has been reported preferentially in
malignant cells (Gritsko et al., 2003; Jeng et al., 2004).
As AURKA can also be detected in normal cells and is
associated with cell proliferation, one may assume that the
higher detection rate of AURKA expression in advanced
stages of MF might be associated with the higher proliferation
rate of malignant cells in comparison with early MF stages.
Nevertheless, our immunohistochemistry results demonstrate
that the proliferation marker Mib-1 is only weakly exhibited in
patch and plaque MF samples in comparison with AURKA.
Hence, proliferation of malignant cells cannot alone explain
the increased expression of AURKA in all MF stages.
Furthermore, there is evidence that the accumulation of
tumor cells in MF is based on resistance to apoptosis, e.g.,
owing to diminished responsiveness to FAS/CD95 ligand and
to tumor necrosis factor–related apoptosis-inducing ligand
rather than enhanced proliferation (Braun et al., 2007, 2010;
Klemke et al., 2009; Wu et al., 2009). On the basis of these
data, we assume that AURKA expression is not associated
with only enhanced proliferation of tumor cells, in line with
ﬁndings in other malignant tumors (Jeng et al., 2004).
The mechanisms of recruitment of AURKA are not
completely understood, but they involve a complex interac-
tion with several proteins, e.g., it regulates the activation of
the polo-like kinase 1 (PLK1) (Macurek et al., 2008), a protein
for which overexpression was recently shown in CTCL (Nihal
et al., 2011; Stutz et al., 2011). Interestingly, recent data
suggest that although AURK activity accelerates mitotic entry
in normal cells, it is essential for mitotic entry only in DNA-
damaged cells, which is the case in CTCL cells harboring a
vast amount of genomic aberrations, as previously shown (van
Vugt et al., 2004; Karenko et al., 2007). Especially, PLK1
seems to be essential for mitotic entry following recovery from
DNA damage. As for AURKA itself, it can activate cell division
cycle 25c (CDC25C) via PLK1 that subsequently promotes
mitotic entry by activating the cyclin B/cyclin-dependent
kinase 1 (CDK1) complex. It has been proposed that CDC25B
acts as the initial starter phosphatase that activates cyclin B/
CDK1, whereas CDC25C has the role to act in a positive
feedback loop with cyclin B/CDK1, leading to full and
irreversible activation (van Vugt et al., 2004). Furthermore, it
could be demonstrated that AURKA can directly phos-
phorylate PLK1 that can additionally be enhanced by the
AURKA activator Bora (Macurek et al., 2008).
In addition to the functions of aurora kinase A in mitosis,
AURKA also regulates the function of TP53 (p53) and NF-κB
that may have important therapeutic implications especially
in CTCL (Braun et al., 2010). AURKA phosphorylates TP53 at
Ser 315, leading to its degradation via ubiquitination by
MDM2 and subsequent proteolysis (Katayama et al., 2004).
In CTCL, we and others could demonstrate a nonfunctional
p53 signaling owing to genomic aberration in up 83% and in
addition owing to frequent mutations in TP53 (Steininger
et al., 2011; Lamprecht et al., 2012). Thus, in CTCL, the
overexpression of AURKA observed here may enhance the
degradation of the remaining function of p53 in CTCL. Thus,
tumor suppressor function of p53 gets lost, causing
tumorigenic transformation of the T lymphocytes. Moreover,
AURKA has been shown to increase NF-κB activity by
phosphorylation of the NF-κB antagonist IκB (Sun et al.,
2007)—a ﬁnding that could contribute to the enhanced
NF-κB activity that is a hallmark in CTCL (Izban et al., 2004;
Sors et al., 2006 and 2008; van Kester et al. 2012).
Several causes for overexpression of AURKA in CTCL are
conceivable. Thus, gene ampliﬁcations have been demon-
strated in CTCLs for a number of overexpressed genes (Vermeer
et al., 2008; Caprini et al., 2009), but frequent genomic
ampliﬁcation of AURKA, which is located at chromosome
position 20q13.3, has not been described. This is in line with
comparative genome hybridization data from our cohort of SS
patients (Steininger et al., 2011), where a gene duplication was
found in only 1/20 patients and only in 1 of 4 investigated CTCL
cell lines. However, in previous reports, it was shown that
overexpression of AURKA can result from overexpressed MYC
(den Hollander et al., 2010; Yang et al., 2010). Indeed, MYC
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Figure 3. Cell viability after Aurora kinase A (AURKA) inhibition in
cutaneous T-cell lymphoma (CTCL) cell lines. (a) Four CTCL cell lines and
phytohemaglutinin (PHA)-stimulated proliferating CD4+ T cells were
incubated with different concentrations of MLN8237 for 48 hours, and the
number of viable cells was determined by WST-1 assay. Values are given in
% of optical density of treated samples compared with samples treated with
solvent (DMSO) after correction by the values of a “medium only” control.
Error bars indicate s.d. of three independent experiments performed in
triplicate. (b) Carboxyﬂuorescein succinimidyl ester (CFSE) staining of
unstimulated (left panel) and PHA-stimulated (right panel) primary CD4+
T cells. In stimulated T cells, the staining intensity is diminished with each
proliferation cycle, proving the proliferation of stimulated cells with a
maximum of three divisions.
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overexpression is a common ﬁnding in CTCL (Steininger
et al., 2011).
To investigate the potential of AURKA inhibition as a
therapeutic approach in CTCL, we performed in vitro experi-
ments with MLN8237, a selective inhibitor of AURKA
(Manfredi et al., 2011). This compound signiﬁcantly inhibited
proliferation of all tested cell lines in a dose-dependent
manner already at low concentrations. In addition, MLN8237
was able to induce apoptosis in Hut-78 cells.
In terms of clinical experience with MLN8237, the safety
and toxicity of this compound was recently investigated in
two phase II multicenter clinical trials in patients with advanced
acute myeloid leukemia and peripheral non-Hodgkin’s lym-
phoma (Goldberg et al., 2010; Friedberg et al., 2014). This
drug showed clinical activity and was generally well tolerated,
causing few nonhematologic toxicities. Dose-limiting toxicity
was neutropenia that has also been observed with most other
AURK inhibitors.
The relatively good toxicity and tolerability proﬁle of
AURKA inhibitors together with the promising preclinical
activity of MLN8237 observed in our study suggest that these
compounds are worth further evaluation in clinical trials
of CTCL.
In conclusion, this study provides preclinical evidence that
AURK inhibitors could be a class of agents active in CTCL.
Although these compounds are not completely selective for
tumor cells, their good tolerability and toxicity proﬁle suggest
that they may represent a useful addition to the current
therapeutic possibilities in CTCL.
MATERIALS AND METHODS
CTCL samples and healthy controls
Tissue samples were embedded in Tissue-Tek OCT, snap-frozen with
dry ice/ethanol, and stored at − 80 °C. SS tumor cells and CD4+
memory cells were isolated from healthy controls, and peripheral
blood mononuclear cells were isolated from whole blood samples or
from leukapheresis samples prepared by density gradient centrifuga-
tion with Ficoll-Paque-Plus (GE Healthcare, Solingen, Germany).
After washing twice with cold phosphate-buffered saline, CD4+ cells
of SS patients were isolated by negative selection using the “CD4+ T
Cell Isolation Kit II, human” (Miltenyi Biotech, Bergisch Gladbach,
Germany). For healthy controls, CD4+ memory T cells were isolated
by negative selection using the “Memory CD4+ T Cell Isolation Kit,
human” (Miltenyi Biotech). All cell sorting was performed according
to the manufacturer’s protocols.
For microarray analysis, 13 lesional skin biopsies of different MF
patients (patch= 3, plaque= 6, tumor= 4) were obtained from
the cutaneous lymphoma bank at the Charité Skin Cancer Center
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Figure 4. Analysis of cell cycle distribution and apoptosis in SeAx, Hut-78,
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for cell cycle distribution and apoptosis induction by propidium iodide
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phases of the cell cycle are as in a. (c) Activation of caspase-3 is demonstrated
by increasing the levels of the activated cleavage products of 15 and 19 kDa in
Hut-78 upon stimulation with 0.1 and 1 μM of the Aurora kinase A (AURKA)
inhibitor MLN8237. In contrast, the caspase-3 proform (37 kDa) and the
loading control glyceraldehyde-3-phosphate dehydrogenase (GAPDH; also
37 kDa) remained unaffected.
D Humme et al.
Aurorakinase A as a Potential Therapeutic Target in CTCL
www.jidonline.org 2297
(Berlin, Germany). To compare microarray data from MF patients
with gene expression data from healthy control tissue, preexisting
expression data of eight healthy control lesions were used that had
been previously obtained at the Rockefeller University (New York,
NY). For quantitative real-time reverse transcriptase–PCR, four CTCL
cell lines, blood samples of 12 highly leukemic, clinically well-
characterized patients with SS, and 9 healthy controls were used.
Samples were obtained at the Charité – Universitätsmedizin Berlin
(Berlin, Germany).
Diagnoses were established according to the current World Health
Organization classiﬁcation for cutaneous lymphomas. The use of
human material was approved by the Local Ethics Committee of the
Charité – Universitätsmedizin Berlin and performed in accordance
with the Declaration of Helsinki Principles.
RNA extraction
Total RNA was isolated using the QiaAmp RNA Blood Mini Kit
(Qiagen, Hilden, Germany) with on-column DNase I digestion
(RNase-free DNase set, Qiagen), according to the manufacturer’s
instructions. RNA concentration was determined by Qubit RNA BR
(Invitrogen, Carlsbad, CA) in a Qubit 1.0 ﬂuorometer. To assess the
quality of total RNA in each sample, extracted RNA was tested using
the Agilent Bioanalyzer 2100 (Agilent Technologies, Palo Alto, CA).
Gene expression proﬁling from CTCL skin samples
RNA ampliﬁcation and reverse transcription into complementary
DNA (cDNA) was performed with the NuGen Ovation Pico RNA
ampliﬁcation system V2 (San Carlos, CA). Subsequently, cDNA was
fragmented with the NuGen Biotin Module according to the
manufacturer’s protocol, and the fragmented cDNA was hybridized
to an Affymetrix array (Affymetrix GeneChip Human Genome HG-
U133 Plus 2.0 Array; Affymetrix, Santa Clara, CA).
Samples from healthy controls were hybridized using the same
protocol. Microarray data sets have been deposited in NCBI
(National Center for Biotechnology Information) Gene Expression
Omnibus and are accessible through Gene Expression Omnibus
series accession number (GSE59307).
AURKA expression proﬁling from SS tumor cells and from
CD4+ memory T cells of healthy controls
For analysis of AURKA expression of SS tumor cells and CD4+
memory cells of healthy controls, cDNA was generated from ∼ 0.5 μg
of total RNA using the “You-Prime ﬁrst-strand beads” (GE Healthcare,
Buckinghamshire, UK) with random hexamer primers according to
the manufacturer’s protocol.
Quantitative real-time PCR of AURKA was performed using a
LightCycler 2.0 device and TBP (TATA box–binding protein)
expression for normalization. The ampliﬁcation reaction mixtures
(20 μl) contained 4 μl of TaqMan Gene Expression Master Mix (Roche
Applied Science, Mannheim, Germany), 1 μl of TaqMan Gene
Expression Assay (Applied Biosystems, Mannheim, Germany), and
2 μl of a 1:5 dilution of cDNA. Ampliﬁcation conditions were as
follows: activation of polymerase for 10 minutes at 95 °C, followed
by 50 cycles of denaturation at 95 °C for 10 seconds, annealing of
primers and probes at 60 °C for 30 seconds, and extension at 72 °C
for 2 seconds. Speciﬁc TaqMan gene expression assays used for real-
time PCR were as follows: Hs01582072_m1 for AURKA and
Hs00427621_m1 for TBP. Each reaction was performed in triplicate.
Normalization of AURKA expression was performed using Q-Gene
1.2 (Muller et al., 2002).
Array comparative genome hybridization
Analyses of the AURKA gene locus 20q13.3 were done by array
comparative genome hybridization, as described previously
(Steininger et al., 2011). DNA copy number changes were deﬁned
by circular binary segmentation in combination with a log2 threshold
of 0.2/− 0.2.
Western blot analyses
For western blotting, total protein extracts were obtained by cell lysis
in 150mM NaCl, 1 mM EDTA, 2 mM PMSF, 1 mM leupeptin, 1 mM
pepstatin, 0.5% SDS, 0.5% NP-40, and 10mM Tris-HCl, pH 7.5.
Western blotting on nitrocellulose membranes was performed as
described previously (Eberle et al., 2003). The following primary anti-
bodies were used: AURKA (Leica Biosystems, Newcastle Upon Tyne,
UK; JLM28, 1:750), Caspase-3 proform (Cell Signaling, Danvers, MA;
9662, rabbit, 1:10,000), cleaved caspase-3 (Cell Signaling; 9664,
rabbit, 1:1,000), and glyceraldehyde-3-phosphate dehydrogenase
(Santa Cruz Biotech, Santa Cruz, CA; sc-3233, mouse, 1:1,000). As
secondary antibodies, peroxidase-labeled goat anti-rabbit and goat
anti-mouse were used (Dako, Hamburg, Germany; 1:5,000).
Immunohistology
A total of 22 parafﬁn-embedded CTCL samples (3 SS and 19 MF)
were analyzed by the anti-AURKA antibody (Leica Biosystems;
JLM28, 1:750). As control samples, 10 cases of inﬂammatory derma-
toses (5 psoriasis vulgaris and 5 eczema) were analyzed. Tissue
sections were counterstained with hematoxylin and semiquantita-
tively analyzed. Positive staining was deﬁned as nuclear or nucleolar,
and in some cases mitotic ﬁgures were also positive.
Stimulation of primary human CD4+ T cells
Primary Human CD4+ T cells were isolated from whole blood from
healthy donors using CD4 MicroBeads, human (Miltenyi Biotech).
Cells were stimulated at a density of 1× 106 cells per well in 1 ml of
medium with 4 μM phytohemaglutinin (Sigma, St Louis, MO) on 24-
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Figure 5. Schematic overview of the interaction of Aurora kinase A (AURKA)
and known decisive factors associated with proliferation and differentiation
in cutaneous T-cell lymphomas (CTCLs).
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well tissue culture plates and incubated at 37 °C and 8% CO2 for
3 days. Cell proliferation was veriﬁed by carboxyﬂuorescein
succinimidyl ester labeling. In brief, primary CD4+ T cells were
washed once in phosphate-buffered saline and resuspended at a
density of 4–10× 106 cells per ml in phosphate-buffered saline.
Freshly prepared carboxyﬂuorescein succinimidyl ester was
immediately added to the cell suspension at a ﬁnal concentration
of 1 μM, and the cells were incubated for 15 minutes at 37 °C.
The carboxyﬂuorescein succinimidyl ester-labeled cells were then
washed two times with RPMI-1640 medium (Biochrom, Berlin,
Germany) supplemented with 10% fetal bovine serum (Biochrom),
and stimulated as described above. As a control, unstimulated cells
were incubated under identical conditions without the addition of
phytohemaglutinin. Cell proliferation was assessed by FACS analysis
on a FACSCalibur ﬂow cytometer using Cell-Quest Pro (Becton
Dickinson, Heidelberg, Germany) and WindMDI 2.9 (The Scripps
Research Institute, La Jolla, CA).
Cell lines and culturing conditions
Six cell lines have been used: SeAx and Hut-78 (both derived from
peripheral blood of a patient with SS), MyLa (derived from a plaque
biopsy of a patient with MF), HH (derived from a tumor nodule of a
patient with aggressive MF/CTCL), Jurkat, and KE-37 (derived from
peripheral blood of a patient with T-cell acute lymphoblastic leukemia).
Cells were cultured at 37 °C and 8% CO2 in RPMI-1640 medium
(Biochrom), and supplemented with L-glutamine (PAA, Austria), 10%
fetal bovine serum (Biochrom), and antibiotics (100 units per ml
penicillin, 100 μgml−1 streptomycin; PAA, Linz, Austria).
AURK inhibition
For AURK inhibition, cells were incubated with the AURKA inhibitor
MLN8237 (Selleckchem, Munich, Germany) and then dissolved in
cell culture–grade DMSO (Sigma-Aldrich) at different concentrations
for 24 or 48 hours.
Cell viability assay
Cell viability was determined using the cell proliferation reagent
WST-1 (Roche), as recommended by the manufacturer.
Cell cycle analysis and detection of apoptosis
Cell cycle analysis and detection of apoptosis was performed by
determination of the cells’ DNA content after staining with propidium
iodide (Riccardi and Nicoletti, 2006). To this end, cells were
harvested by centrifugation, resuspended with cold phosphate-
buffered saline, ﬁxed with prechilled ethanol at − 20 °C for at least
24 hours, and stained for 40 minutes in a 500-μl solution containing
propidium iodide (50 μg ml−1), RNase A (0.1 mgml− 1), and 0.05%
Triton X-100. The DNA content was then determined by ﬂow
cytometry on a FACSCalibur ﬂow cytometer using Cell-Quest Pro
(Becton Dickinson) and WindMDI 2.9 (The Scripps Research
Institute).
Statistical analysis
Microarray data were analyzed with the Genespring GX version 10.0
software (Agilent) and R/Bioconductor packages (Seattle, WA). The
Harshlight package was used to scan Affymetrix chips for spatial
artifacts (Suárez-Fariñas et al., 2005). Expression values were
obtained using the GCRMA (GC Robust Multiarray Average)
procedure. Quality control of the expression values was carried out
using the Bioconductor package arrayQualityControl.
Genes with s.d.40.1 and log2-transformed expression43 in at least
2 samples were kept for analyses. Differential expression between
lesional MF samples and healthy control tissue was assessed using a
moderated Student’s t-test followed my multiple corrections using the
Benjamini–Hochberg procedure using the framework of Bioconductor’s
limma package. Genes with false discovery rateo0.05 and fold change
42.0 were considered differentially expressed genes.
Differential expression between SS tumor cells and healthy
controls was assessed using REST 2009 V2.0.13 (Qiagen). Cell
viability results were analyzed by paired, two-tailed t-test.
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